Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response

Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors

(2021) A. Gault et al.   BRITISH JOURNAL OF DERMATOLOGY

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study

(2021) M. Guida et al.   ESMO Open

Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma

(2021) Eleonora Farinazzo et al.   MELANOMA RESEARCH

Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences

(2020) Brandon E. Cohen et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy

(2019) Francesca Consoli et al.   PLoS One

Immunological effects of BRAF+MEK inhibition

(2018) Paolo A. Ascierto et al.   OncoImmunology

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600–mutant metastatic melanoma

(2018) Guy Ben-Betzalel et al.   EUROPEAN JOURNAL OF CANCER

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo

(2017) Maiana Larsabal et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH